applications: biomarker and molecular discovery, and clinical risk prediction and decision support.

Every engagement runs through a structured program model with defined phases, repeatable methodology, and findings built for the partner's commercial roadmap. The platform integrates multiomic, clinical, and real-world data sources and runs standardized analytical steps from data ingestion and QC through multi-method ML modeling and results synthesis. It is disease-agnostic and can be extended to new conditions without rebuilding.

Decode's work is peer-reviewed and published in leading journals, supported by more than $2.2M in competitive NIH/NIAID SBIR funding, and has been presented at major scientific venues. The platform improves with each program: every engagement adds to a more calibrated pipeline, a richer proprietary data estate, and a deeper body of validated methodology.

Founded in Nashville in 2019. Recognized by Inc. Magazine as one of the Top 100 companies in the Southeast.